<DOC>
	<DOCNO>NCT02760316</DOCNO>
	<brief_summary>A study ass safety , tolerability , pharmacokinetics pharmacodynamics multiple ascend dos AZD9567 .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Ascending Doses AZD9567 .</brief_title>
	<detailed_description>This phase 1 , randomise , single-blind , multiple ascend dose , double-dummy sequential group study healthy subject . The study plan 4 cohort option include two additional cohort deem necessary . Nine subject participate first cohort ( 7 subject randomise receive AZD9567 2 subject randomise receive prednisolone 20 mg ) eleven subject participate subsequent cohort ( 7 subject randomise receive AZD9567 4 subject randomise receive prednisolone 20 mg ) . Four dose level AZD9567 plan test study therefore two additional cohort use case previous dose need repeat new low dose explore . Therefore maximum 64 individual could include study ( 9 1st cohort ( state version 2.0 protocol ) 11 subsequent cohort ( state version 3.0 ) ) . Subjects dose 5 consecutive day follow-up visit occur 10-14 day last dose .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Male nonchildbearing potential female subject , age 18 55 year ( inclusive ) suitable vein cannulation repeat venipuncture . Explanatory note : Female subject must nonchildbearing potential , confirm screen fulfilling study predefined criterion 2 . Body mass index ( BMI ) 18 29.9 kg/m2 inclusive weigh least 50 kg 100 kg inclusive . 3 . Serum cortisol level within normal limit Screening ( collect part clinical chemistry panel ) discretion Investigator . 4 . Able understand , read speak language ICD approve EC/IRB 5 . Provision sign date , write informed consent prior study specific procedure . 1 . History clinically important disorder , opinion Investigator , may either put subject risk influence result subject 's ability participate study . 2 . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . History presence dyspepsia oral intolerance steroid . 4 . History active latent tuberculosis ( TB ) , risk acquire TB ( social worker prison staff country endemic rate TB , live patient know TB ) . 5 . History suggest abnormal immune function , judge Investigator . 6 . History severe affective disorder include depressive maniacdepressive illness . 7 . History previous steroid psychosis 8 . Any clinically important illness , medical/surgical procedure , trauma within 4 week first administration IMP . 9 . Any latent chronic infection risk infection , history skin abscess within 90 day prior first administration IMP discretion Investigator . 10 . Any clinically important laboratory abnormality ( serum biochemistry , hematology , coagulation urinalysis result ) Screening prior randomisation , judge Investigator . Explanatory note : In particular subject abnormal value ( 2x upper level normal ) alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , serum creatinine ( 1.2x upper level normal ) , and/or upper level normal serum bilirubin , abnormal value haemoglobin ( Hb ) , white blood cell ( WBC ) and/or absolute neutrophil count normal limit exclude . 11 . Any positive result Screening serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody and/or human immunodeficiency virus ( HIV ) . 12 . Abnormal vital sign 10 minute supine rest . Explanatory note : Deviations normal vital sign within follow range allow follow : Systolic BP ( SBP ) &lt; 90mmHg &gt; 140 mmHg Diastolic BP ( DBP ) &lt; 50mmHg &gt; 90 mmHg Heart rate &lt; 50 &gt; 90 beat per minute ( bpm ) 13 . Any clinically important abnormality rhythm , conduction morphology rest ECG 12lead ECG may interfere interpretation QTc change Explanatory note : also include abnormal STTwave morphology , particularly protocol define primary lead leave ventricular hypertrophy . 14 . Prolonged QTcF &gt; 450 ms family history long QT syndrome . 15 . PR ( PQ ) interval shorten &lt; 120 m ( PR &gt; 110 m &lt; 120 m acceptable evidence ventricular preexcitation ) . 16 . PR ( PQ ) interval prolongation ( &gt; 240 m ) intermittent second ( Wenckebach block asleep exclusive ) third degree AV block , AV dissociation . 17 . Persistent intermittent complete bundle branch block ( BBB ) , incomplete bundle branch block ( IBBB ) , intraventricular conduction delay ( IVCD ) QRS &gt; 110 ms. Explanatory note : Subjects QRS &gt; 110 m &lt; 115 m acceptable evidence , example , ventricular hypertrophy preexcitation . 18 . Known suspected history drug abuse last 6 month , judge Investigator . 19 . Smokers smoke â‰¥ 5 cigarettes/pipes per day , use tobacco form . Smoking allow study treatment period ( Day 2 Day 6 ) ( 1 ecigarette = 1 cigarette ) . 20 . History alcohol abuse excessive intake alcohol , judge Investigator . 21 . Positive screen drug abuse alcohol Screening admission clinical unit . 22 . History severe allergy/hypersensitivity ongoing clinically important allergy/hypersensitivity drug similar chemical structure class study drug . 23 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea , chocolate ) , judge Investigator . 24 . Receipt live live attenuate vaccine within 4 week prior first administration IMP . 25 . Use drug enzyme induce property St John 's Wort within 3 week prior first administration IMP . 26 . Use prescribed nonprescribed medication two week prior first administration IMP long medication long halflife . Explanatory note : prohibit medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) minerals 27 . Plasma donation within one month screen blood donation/blood loss &gt; 500 mL 3 month prior screen . 28 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month 5 halflifes , whatever long first administration IMP . Explanatory note : period exclusion begin three month final dose one month last visit whichever long . Subjects consent screen , randomise study previous phase I study , exclude . 29 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order . 30 . Involvement Astra Zeneca PAREXEL study site employee close relative . 31 . Judgment Investigator subject participate study Explanatory note : example , subject ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data , consider unlikely comply study procedure , restriction requirement , subject randomise . 32 . Subject vegan medical dietary restriction . 33 . Subject communicate reliably Investigator/site staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Obese</keyword>
	<keyword>Insulin Resistant Subjects</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>